/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Ernexa Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.21 -0.0417(-4.17%) ERNA at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 1.12
Highest Today 1.19
Today’s Open 1.18
Prev. Close 1.2
52 Week High 11.10
52 Week Low 1.09
Day’s Range: Low 1.12 High 1.19
52-Week Range: Low 1.09 High 11.10
1 day return -
1 Week return -10.54
1 month return -34.57
3 month return -9.12
6 month return +557.66
1 year return +274.91
3 year return -74.15
5 year return -98.58
10 year return -

Institutional Holdings

Geode Capital Management, LLC 0.26

CI Private Wealth LLC 0.23

Fidelity Extended Market Index 0.17

Vanguard Institutional Extnd Mkt Idx Tr 0.14

Sippican Capital Adivsors 0.13

Fidelity Series Total Market Index 0.04

Spartan Extended Market Index Pool F 0.04

BlackRock Inc 0.01

Spartan Total Market Index Pool G 0.01

Morgan Stanley - Brokerage Accounts 0.01

UBS Group AG 0.01

Fidelity Total Market Index 0.00

Genworth Financial Wealth Mgmt Inc 0.00

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Bank of America Corp 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

SSgA U.S. Total Market Index Strategy 0.00

BNYM Mellon SL Market Completion UC1 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

A. Montag & Associates Inc 0.00

BNP Paribas Arbitrage, SA 0.00

Northern Trust Wilshire 5000 0.00

State St US Ttl Mkt Indx NL Cl A 0.00

Activest Wealth Management 0.00

BNYM Mellon NSL Mkt Completion Fund Inst 0.00

Citadel Advisors Llc 0.00

Cypress Point Wealth Management, LLC 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

FMR Inc 0.00

Goldman Sachs Group Inc 0.00

Guggenheim Active Allocation Fund 0.00

JustInvest LLC 0.00

Millennium Management LLC 0.00

one8zero8, LLC 0.00

SBI Securities Co Ltd 0.00

Susquehanna International Group, LLP 0.00

Market Status

Fundamentals

Market Cap 9.42 M

PB Ratio 2.749

PE Ratio 0.0222

Enterprise Value 7.32 M

Total Assets 5.27 M

Volume 83907

Company Financials

Annual Revenue FY23:51000 0.1M, FY22:0 0.0M, FY21:0 0.0M, FY20:5800000 5.8M, FY19:19806000 19.8M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:-5765000 -5.8M, FY20:5599000 5.6M, FY19:19446000 19.4M

Annual Net worth FY23:-20004000 -20.0M, FY22:-24579000 -24.6M, FY21:-122306000 -122.3M, FY20:11906000 11.9M, FY19:-2047000 -2.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:487000 0.5M, Q2/2024:47000 0.0M

Quarterly Profit Q3/2025:0 0.0M, Q2/2025:-55000 -0.1M, Q1/2025:-69000 -0.1M, Q3/2024:547000 0.5M, Q2/2024:-48000 -0.0M

Quarterly Net worth Q3/2025:-1240000 -1.2M, Q2/2025:-3139000 -3.1M, Q1/2025:-8202000 -8.2M, Q3/2024:-26604000 -26.6M, Q2/2024:-5529000 -5.5M

Fund house & investment objective

Company Information Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 6

Industry Biotechnology

CEO Mr. Sanjeev Luther

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow